Servier (@Servier) / Twitter
Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
Claude Bertrand's email & phone | Servier's Executive Vice President R and D, Chief Scientific Officer email
Frédéric VIGNERON - Industrial Excellence Consultant - Servier | LinkedIn
Dr Claude Bertrand, General Director of Research and Development at Servier - Servier
Ivosidenib/Azacitidine Significantly Improves EFS in Previously Untreated IDH1-Mutated AML
Our Team - Abivax
Pose de la première pierre du nouvel Institut de recherche de Servier à Paris-Saclay - Etablissement public d'aménagement Paris-Saclay (EPAPS)
Comment Servier a transformé sa R&D
Claude Bertrand - United Kingdom | Professional Profile | LinkedIn
Our Team - Abivax
Claude Bertrand - United Kingdom | Professional Profile | LinkedIn
Servier backs an American startup at LabCentral in the
Mediator : la face cachée de Jacques Servier
Our Team - Abivax
Claude Bertrand - United Kingdom | Professional Profile | LinkedIn
News
Servier : Claude Bertrand est nommé directeur général de la R&D- AEFinfo
Servier on Twitter: "We are always exploring different ways to serve patients' needs. This includes #research & #development of monoclonal antibodies to fight against #cancer. Learn more about our latest announcements👉https://t.co/Q84thhbOsh https://t ...
MaaT Pharma Appoints Claude Bertrand, Servier's Executive Vice President of R&D, as Independent Board Member and Welcomes New Chief Medical Officer John Weinberg | Business Wire
News
Server cans autism hope bumetanide after phase 3 fails -
SERVIER : DES ALLIANCES PLUS RENTABLES - Biotech Finances
